Linagliptina Generis

Linagliptin, the active ingredient in Linagliptina Generis, is a DPP-4 inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adults. GNH USA supplies Linagliptina Generis as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is used to improve glycaemic control in patients with type 2 diabetes mellitus, acting on the incretin pathway. - Type 2 diabetes mellitus: improves glycaemic control as monotherapy. - Type 2 diabetes mellitus (combined with metformin): enhances overall glucose lowering. - Type 2 diabetes mellitus (adjunct to diet and exercise): supports maintenance of target HbA1c levels.

Linagliptin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nasopharyngitis: mild upper respiratory infection symptoms. - Headache: transient mild to moderate pain. - Upper respiratory tract infection: cough, sore throat. - Gastrointestinal discomfort: nausea or abdominal pain. - Arthralgia: joint pain without swelling.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic injury: elevated liver enzymes or jaundice. - Bullous skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Severe hypoglycaemia: when combined with insulin or sulfonylureas.

Before prescribing Linagliptina Generis, clinicians should consider several safety aspects. - Renal impairment: assess kidney function; dose adjustment may be needed. - Hepatic impairment: monitor liver enzymes and adjust therapy if necessary. - Cardiovascular disease: use with caution in patients with unstable heart conditions. - Concomitant antidiabetic agents: monitor for increased risk of hypoglycaemia. - Pregnancy and breastfeeding: safety not established; avoid unless benefits outweigh risks. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Linagliptin may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce linagliptin exposure. - Insulin or sulfonylureas: can increase risk of severe hypoglycaemia.

Moderate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., ketoconazole): may raise linagliptin plasma levels. - Diuretics: monitor electrolytes and renal function. - Warfarin: observe INR values for potential anticoagulant effect changes.